Clearside Biomedical (NASDAQ:CLSD – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03, Zacks reports.
Clearside Biomedical Trading Up 1.0 %
Shares of NASDAQ CLSD traded up $0.01 during trading on Thursday, reaching $1.03. The company had a trading volume of 152,176 shares, compared to its average volume of 356,922. The stock has a market capitalization of $78.12 million, a PE ratio of -2.29 and a beta of 2.10. Clearside Biomedical has a twelve month low of $0.77 and a twelve month high of $1.76. The stock has a 50-day moving average price of $0.96 and a two-hundred day moving average price of $1.05.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, March 6th. StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Tuesday, March 18th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Clearside Biomedical currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.75.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- Stock Sentiment Analysis: How it Works
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Financial Services Stocks Investing
- Top 3 Beverage Stocks Pouring Out Profits
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
